Oslo Innovation Week, on behalf of the City of Oslo and Innovation Norway, has announced that the medical technology startup, EpiGuard is the recipient of the 2021 Oslo Innovation Award.
Nordic Life Science
NOT A SUBSCRIBER? SIGN UP TODAY AND GET THE FULL LIFE SCIENCE PICTURE
ONLY 13 €/MONTH
NLS News
Ascelia Pharma has signed an agreement with Taiho Oncology, a subsidiary of Taiho Pharmaceutical. The collaboration concerns an upcoming global Phase 2 clinical study in gastric cancer. In this all-oral
The boards of Coegin Pharma and Follicum have assumed a merger plan in order to implement a merger of Coegin Pharma and Follicum through a limited company legal fusion. The
AstraZeneca is to invest 360 million USD in an advanced manufacturing facility in Ireland. The investment will transform development and commercialization of new medicines, states the company. “This is a
Aegirbio acquires the health tech company Dynamic Code, and states that it is now embarking on the strategic construction of an international operator in the rapidly evolving domain of e-health.
Intrance Medical Systems Inc, a subsidiary of Sweden-based Intrance Holdings AB, has secured financing from Swedish real estate investor Erik Selin through his private company, Erik Selin Fastigheter AB. Erik
The company’s universal cancer vaccine, UV1, in combination with the checkpoint inhibitor pembrolizumab, has recently demonstrated a 60% objective response rate in metastatic malignant melanoma. Nordic Life Science asked the
The Research Council of Norway recently awarded a grant to the new company NordicRWE. NordicRWE was granted 16 million NOK for their research and development (R&D) project that will focus
Bioneer has announced a strategic collaboration with the National Biologics Facility (NBF) to commercialize their combined CRO services for mammalian expression of recombinant proteins. The entity, previously named CHO CORE,
Calliditas Therapeutics has announced that the U.S. Food and Drug Administration has extended the PDUFA goal date for its New Drug Application (NDA) seeking accelerated approval for Nefecon to December
Diamyd Medical has announced the acquisition of the property in Umeå where production of the recombinant protein GAD65, the active component in the therapeutic diabetes vaccine Diamyd is being established.
Following results from a phase 2 study of FOL-005, for the treatment of hair loss, the Board of the company decided to evaluate the company’s business strategy and long-term goals.
Although the world is still struggling with the corona virus and new mutations, things are slowly but surely getting back to a somewhat normal situation. The life science area has
Immunovia has strengthened its patent protection for pancreatic cancer biomarkers by obtaining a global license from the South Korean company JW BioScience’s IP portfolio. The license agreement gives Immunovia global
The COVID-19 pandemic
The vaccine platform developed by Abera Bioscience has been used in a collaboration between researchers at Johns Hopkins University School of Medicine (Baltimore, USA) and Vrije Universiteit (Amsterdam, the Netherlands)
The company is expecting to communicate results from a recently concluded Phase 2 trial of its drug candidate Rabeximod in COVID-19 patients during the fourth quarter. The results were previously
Vicore Pharma has announced that the US Patent and Trademark Office (USPTO) has granted a patent covering the use of C21 to treat infections caused by Severe Acute Respiratory Syndrome
SARS-CoV-2 can attach to not one but two receptors on the host cell surfaces shows new Danish research. In 2003, the SARS epidemic caused panic in 26 countries on six
AZD7442, a combination of two long-acting antibodies (LAAB), reduced the risk of developing symptomatic COVID-19 by 77%, compared to placebo. The Phase III trial accrued 25 cases of symptomatic COVID-19
NextCell Pharma has announced that a patent application has been filed for the treatment of Sars-CoV-2 mediated severe pneumonia with ProTrans. NextCell increases the IP protection for the drug candidate
The vaccine platform developed by Abera Bioscience has been used in a collaboration between researchers at Johns Hopkins University School of Medicine and Vrije Universiteit to produce and test a
Drug and device development
AlzeCure Pharma has received approval from the regulatory authorities in Sweden to begin the next clinical phase I study (multiple ascending dose, MAD) with the candidate drug ACD856 focused on
Positive results from the PROpel Phase III trial showed that AstraZeneca and MSD’s Lynparza (olaparib) in combination with abiraterone demonstrated a statistically significant and clinically meaningful improvement in radiographic progression-free
SynAct Pharma completes patient recruitment to the Phase 2a BEGIN study of AP1189 in early severe Rheumatoid Arthritis. With all patients included into the study, dosing will be concluded in
RhoVac’s clinical phase IIb study of lead drug candidate RV001 in prostate cancer, BRaVac, is deemed fully recruited and no additional patients will be screened after this week. Top-line results
Updated results from the Phase III trial showed that Imfinzi (durvalumab) in combination with a choice of chemotherapies, etoposide plus either carboplatin or cisplatin, demonstrated a sustained, clinically meaningful overall
Profile
Driven by the curiosity of nature’s secrets, Jennifer Doudna, Nobel Laureate in Chemistry 2020, has devoted her life to the mysteries of biochemistry and cracking a game-changing code. Jennifer Doudna’s
In a new job
The pandemic has led to several changes in our working lives, including new digital tools, new kinds of offices and more work-life balance. But it has also meant loss of
Already making a mark as director of the Center for Regional Development, the Capital Region of Denmark, Diana Arsovic Nielsen has taken on a new role as the CEO of
Swedish pharmaceutical company LIDDS has appointed Nina Herne as its new CEO. LIDDS has developed a drug delivery technology, NanoZolid, which provides a controlled and sustained release of active drug
Careers
Jennie Ekbeck, CEO at Umeå Biotech Incubator, has been appointed Innovations Angel of 2015. With her drive and problem-solving mindset she wants to make exciting research into business ideas and
Read the latest issue of our magazine!
No 03 2021 // The Nordic life science industry has not only survived, but managed to grow and develop during the pandemic. Read more about how the past 1.5 years have also brought valuable lessons, including the importance of collaboration and how to shorten development pathways in other areas too.
Our profile in this issue, Malin Parkler, CEO, Pfizer Sweden, shares her thoughts on leadership, the future of healthcare and Nordic life sciences, and the importance of staying curious. We have also taken a closer look at US life sciences under President Biden, three Nordic startups share their journeys so far and their advice to aspiring life science entrepreneurs, and much more!
Venture Capital
Nordic Life Science asked Fredrik Dahl, co-founder at Colibri Ventures, what Nordic venture capitalists are looking for today within life sciences and what current opportunities and challenges Nordic life science
Nordic Life Science asked Claus Andersson, General Manager at Sunstone Life Science Venture, what Nordic venture capitalists are looking for today within life sciences and what current opportunities and challenges
Nordic Life Science asked Inka Mero, Founder and Managing Partner at Voima Ventures, what Nordic venture capitalists are looking for today within life sciences and what current opportunities and challenges
“Start by asking what the problem is that you are trying to solve and develop the technology, team, and plan to solve that problem – not what you can do with the technology.” – Fredrik Dahl, Colibri Ventures
Upcoming events
This one day live and virtual event provides insights and future trends aiming to inspire and stimulate fruitful collaborations. The event gathers representatives from industry, academia, and the healthcare sector
The Swedish-American Life Science Summit (SALSS) 2021 will take place in Stockholm, Sweden, on October 20-22. The focus on the event will be cell and gene therapy and a crucial
This event will offer a week of biotech, pharma and finance. The digital event will include one-to-one meetings, company presentations, company showcase and interesting keynotes and panels. Read more about
Outsourcing in Clinical Trials & Clinical Trial Supply Nordics – This event gathers the pharmaceutical, biotechnology, and medical device communities to discuss strategies for operational success in clinical trials. With
The latest research news from the Nordic region
Science Article
Scientists at Icelandic deCODE genetics have found a new biomarker for osteoarthritis, that outperforms previously reported biomarkers and is an independent predictor of disease. In a study published in the
Researchers at the University of Helsinki are growing a human-derived mini-brain from stem cells, containing all of the most important cell types of the human brain. The mini-brain can be
Scientists have identified 15 novel biomarkers that are linked to late-onset dementias. These biomarkers are proteins, which predict cognitive decline and subsequent increased risk of dementia already 20 years before
With the application of a novel 3D imaging technology, researchers at Karolinska Institutet have discovered that one portion of the autonomic nervous system in the liver undergoes severe degeneration in
Researchers at Karolinska Institutet have developed a detailed molecular atlas of the fetal development of the brain. “Brain development is well described and the main cell types are known. What
Researchers at Uppsala University and Karolinska Institutet have presented a new screening approach that focuses on the identification of virus-specific morphological changes in virus-infected cells. The new method focuses on
Nordic Life Science
The latest clinical trials
Positive results from the PROpel Phase III trial showed that AstraZeneca and MSD’s Lynparza (olaparib) in combination with abiraterone demonstrated a statistically significant and clinically meaningful improvement in radiographic progression-free
SynAct Pharma completes patient recruitment to the Phase 2a BEGIN study of AP1189 in early severe Rheumatoid Arthritis. With all patients included into the study, dosing will be concluded in
RhoVac’s clinical phase IIb study of lead drug candidate RV001 in prostate cancer, BRaVac, is deemed fully recruited and no additional patients will be screened after this week. Top-line results
Updated results from the Phase III trial showed that Imfinzi (durvalumab) in combination with a choice of chemotherapies, etoposide plus either carboplatin or cisplatin, demonstrated a sustained, clinically meaningful overall
The vaccine platform developed by Abera Bioscience has been used in a collaboration between researchers at Johns Hopkins University School of Medicine (Baltimore, USA) and Vrije Universiteit (Amsterdam, the Netherlands)
Cantargia receives regulatory approval to start CESTAFOUR clinical study with nadunolimab in combination with chemotherapy. The company has announced approval to start the phase I/II clinical study by the regulatory
Positive results from the Phase III trial showed that AstraZeneca’s Imfinzi and tremelimumab, when added to platinum-based chemotherapy, demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS)
The two companies have announced dosing of the first patient in the global ASPIRE Phase 2 trial evaluating izokibep (IMG-020 or ABY-035) for the treatment of Ankylosing Spondylitis (AS). ASPIRE
Positive results from the trial in Wilson disease showed that ALXN1840 met the primary endpoint with a statistically significant improvement in daily mean copper mobilization from tissues, demonstrating superiority compared
Sign up to our newsletter